Video

'Out of the Blue' Diagnosis Linked to a Family History of Cancer Now Empowers Others

Sue Friedman, founder and executive director of FORCE, discussed how a breast cancer diagnosis at age 33 and a family history of cancer led to the creation of Facing Our Risk of Cancer Empowered.

A breast cancer diagnosis at the age of 33 that felt like it was “out of the blue” led to the creation of Facing Our Risk of Cancer Empowered (FORCE).

Founder and executive director Sue Friedman was inspired to found the organization following her own cancer diagnosis and eventual linkage to family history with cancer. It wasn’t until 1996, “the early days of genetic testing,” that Friedman read an article about hereditary cancers and genetic testing. She then began to understand some of the factors that put her at risk.

At the 2019 American Society of Clinical Oncology Annual Meeting, Friedman discussed her journey and why she immediately began FORCE following the conclusion of her treatment. “I didn’t think anyone should have to face this challenge alone,” she said.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of woman with text.
Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute.
Kidney Cancer Research Embraces Biology-Driven Precision Approach
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Related Content